Your browser doesn't support javascript.
loading
Racial Differences in Medications for Opioid Use Disorder Initiation in a Carceral Setting.
Berk, Justin; Brar, Jessica; Hoadley, Ariel; Martin, Rosemarie.
Affiliation
  • Berk J; Department of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.
  • Brar J; Department of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.
  • Hoadley A; Department of Social and Behavioral Sciences, Temple College of Public Health, Philadelphia, PA, USA.
  • Martin R; Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown School of Public Health, RI, USA.
Subst Use Addctn J ; : 29767342241273417, 2024 Sep 02.
Article de En | MEDLINE | ID: mdl-39219484
ABSTRACT

BACKGROUND:

The opioid overdose crisis significantly affects marginalized communities, with people of color experiencing higher rates of overdose and barriers to treatment. The syndemic of opioid use disorder and mass incarceration exacerbates racial health disparities. Some carceral facilities offer medication for addiction treatment, though no significant research explores differences in type of treatment uptake by race in these settings. This study focuses on the racial differences in medications for opioid use disorder (MOUD) preferences among incarcerated individuals.

METHODS:

A retrospective cohort study was conducted at the Rhode Island Department of Corrections (RIDOC), examining MOUD-type preferences (buprenorphine or methadone) among incarcerated individuals. The study utilized RIDOC electronic medical records from January 1, 2017 to December 31, 2022, involving 3533 unique incarceration events. Participants were categorized by race (White vs non-White) and MOUD status (new initiation vs community continuation), with logistic regression models.

RESULTS:

The study found no direct racial disparity in preferences for MOUD type. However, an interaction between race and MOUD initiation status significantly influenced MOUD-type preference. Among those initiating MOUD during incarceration, non-White individuals were more likely to choose buprenorphine compared to their White counterparts.

CONCLUSIONS:

This research provides new insights into the intersection of race, incarceration, and MOUD preferences. While direct racial disparities in MOUD type were not observed, the analysis uncovered a notable interaction effect race influences the relationship between MOUD initiation status and the selected MOUD treatment during incarceration. Specifically, data demonstrate that the likelihood of choosing buprenorphine varies significantly based on both racial background and whether the treatment was initiated during incarceration or in the community. Further research is needed in different geographic settings to understand the broader implications to help guide equitable healthcare delivery in jails and prisons.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Subst Use Addctn J Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Subst Use Addctn J Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique